Bio-Path (NASDAQ:BPTH) Rating Reiterated by Roth Mkm

Bio-Path (NASDAQ:BPTH)‘s stock had its “buy” rating restated by equities researchers at Roth Mkm in a report released on Thursday, Benzinga reports. They currently have a $40.00 target price on the stock.

Separately, StockNews.com assumed coverage on Bio-Path in a research report on Tuesday. They set a “sell” rating for the company.

Bio-Path Trading Up 2.1 %

Shares of NASDAQ BPTH opened at $4.29 on Thursday. Bio-Path has a twelve month low of $2.70 and a twelve month high of $44.80. The company has a market capitalization of $2.91 million, a price-to-earnings ratio of -0.11 and a beta of 0.35. The business has a 50 day simple moving average of $5.40 and a 200-day simple moving average of $8.51.

Bio-Path (NASDAQ:BPTH) last issued its quarterly earnings results on Friday, March 8th. The company reported ($5.40) earnings per share for the quarter, meeting analysts’ consensus estimates of ($5.40). During the same period in the prior year, the company earned ($10.60) earnings per share. As a group, equities analysts predict that Bio-Path will post -18.71 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in Bio-Path by 77.5% during the 4th quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock valued at $125,000 after purchasing an additional 117,914 shares during the period. Walleye Capital LLC acquired a new position in Bio-Path during the 3rd quarter worth $77,000. Renaissance Technologies LLC acquired a new position in Bio-Path during the 2nd quarter worth $70,000. Virtu Financial LLC acquired a new position in Bio-Path during the 1st quarter worth $38,000. Finally, Citadel Advisors LLC acquired a new position in Bio-Path during the 3rd quarter worth $35,000. Institutional investors and hedge funds own 5.74% of the company’s stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.